Keyphrases
Beta-blockers
100%
Prognostic Value
100%
Non-small Cell Lung Cancer (NSCLC)
100%
Pembrolizumab
100%
Metastatic Non-small Cell Lung Cancer
44%
Progression-free Survival
33%
Overall Survival
33%
Cancer Initiation
11%
Cancer Progression
11%
High Prevalence
11%
Multivariate Analysis
11%
Retrospective Analysis
11%
Cardiovascular Risk
11%
Cardiovascular Disease
11%
Disease Progression
11%
Immune Checkpoint Inhibitors
11%
Risk Disease
11%
Heart Failure
11%
Atrial Fibrillation
11%
Ischemic Heart Disease
11%
Cardiac Risk
11%
Immune Checkpoint Inhibitor Therapy
11%
Median Overall Survival
11%
β-adrenergic Signaling
11%
Lung Cancer Patients
11%
Nonselective β-blockers
11%
First-line Pembrolizumab
11%
Medicine and Dentistry
Pembrolizumab
100%
Non Small Cell Lung Cancer
100%
Beta 1 Adrenergic Receptor Blocking Agent
100%
Overall Survival
80%
Progression Free Survival
60%
Immune Checkpoint Inhibitor
40%
Disease
20%
Malignant Neoplasm
20%
Ischemic Heart Disease
20%
Prevalence
20%
Cardiovascular Risk
20%
Cardiovascular Disease
20%
Multivariate Analysis
20%
Lung Cancer
20%
Heart Failure
20%
Atrial Fibrillation
20%
Beta Adrenergic Receptor Blocking Agent
20%
Disease Exacerbation
20%
Pharmacology, Toxicology and Pharmaceutical Science
Pembrolizumab
100%
Non Small Cell Lung Cancer
100%
Beta 1 Adrenergic Receptor Blocking Agent
100%
Overall Survival
80%
Progression Free Survival
60%
Immune Checkpoint Inhibitor
40%
Disease
20%
Malignant Neoplasm
20%
Prevalence
20%
Cardiovascular Risk
20%
Ischemic Heart Disease
20%
Cardiovascular Disease
20%
Beta Adrenergic Receptor Blocking Agent
20%
Heart Failure
20%
Atrial Fibrillation
20%
Lung Cancer
20%
Disease Exacerbation
20%